Alexandre A. Theocharides
Zurich, ZH, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications
Publisher Correction: Feasibility of multiomics tumor profiling for guiding treatment of melanoma.
Journal: Nature medicine
Published: August 01, 2025
A tumor profiling resource for ovarian cancer: insights into chemotherapy-driven heterogeneity and personalized treatment strategy.
Journal: Nature communications
Published: March 09, 2025
Loss of SMAD1 in acute myeloid leukemia with KMT2A::AFF1 and KMT2A::MLLT3 fusion genes.
Journal: Frontiers in oncology
Published: August 16, 2024
Feasibility of multiomics tumor profiling for guiding treatment of melanoma.
Journal: Nature medicine
Published: July 09, 2024
Editorial: The therapeutic inhibition of macrophage checkpoints.
Journal: Frontiers in immunology
Published: April 16, 2024
The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect.
Journal: Cancer research
Published: April 05, 2024
Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia.
Journal: Nature communications
Published: March 08, 2024
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
Journal: European journal of haematology
Published: May 26, 2023
Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis.
Journal: Nature communications
Published: October 22, 2022
CALR loss-of-heterozygosity as a potential driver for extramedullary AML.
Journal: Annals of hematology
Published: July 28, 2022
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms.
Journal: Nature cancer
Published: July 27, 2022
Last Updated: 09/26/2026